TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35104297

Group type: EXPERIMENTAL
Intervention: Pictorial warnings on sugary drinks (warnings about type 2 diabetes and heart damage)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Pictorial warnings on sugary drinks
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control arm (barcode label)
Number of subjects: 325
Study: 34168337

Group type: EXPERIMENTAL
Intervention: Randomization null models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 32347687

Group type: EXPERIMENTAL
Intervention: mIOL
Number of subjects: 100

Group type: COMPARATOR
Intervention: IOL
Number of subjects: 100
Study: 34724559

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 731

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Low-maximum lysis
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Normal maximum lysis
Number of subjects: 731
Study: 32385554

Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine solution (CHG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10% benzoyl peroxide soap (BPO)
Number of subjects: 50
Study: 34114501

Group type: EXPERIMENTAL
Intervention: Bioabsorbable bone hemostatic agent (BBHA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 34246129

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation (PNF) exercises
Number of subjects: 53
Study: 34015041

Group type: EXPERIMENTAL
Intervention: 2-day levofloxacin treatment
Number of subjects: 241

Group type: COMPARATOR
Intervention: CRP-guided levofloxacin treatment
Number of subjects: 241
Study: 33074327

Group type: EXPERIMENTAL
Intervention: Bimagrumab 700 mg monthly for 6 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 35380078

Group type: COMPARATOR
Intervention: Placebo-siponimod
Number of subjects: 0
Study: 32872052

Group type: EXPERIMENTAL
Intervention: XCARE technology spiral CT scan
Number of subjects: 560

Group type: COMPARATOR
Intervention: Conventional low-dose spiral CT scan
Number of subjects: 560
Study: 35758442

Group type: EXPERIMENTAL
Intervention: Dual trigger using gonadotropin releasing hormone agonist with human chorionic gonadotropin (hCG)
Number of subjects: 90

Group type: COMPARATOR
Intervention: hCG alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (Dual trigger and hCG alone)
Number of subjects: 90
Study: 34060901

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 552

Group type: COMPARATOR
Intervention: other regimens
Number of subjects: 552
Study: 35854370

Group type: EXPERIMENTAL
Intervention: Multicomponent policy package implemented for 6 months in preschools randomized to intervention
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group (preschools not receiving the intervention)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Multicomponent policy package
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4000
Study: 33411801

Group type: EXPERIMENTAL
Intervention: Flexible parametric model with frailty (df = 2)
Number of subjects: 596
Study: 32833767

Group type: COMPARATOR
Intervention: Standard Time to Surgery (TTS) 4-6 weeks
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Prolonged Time to Surgery (TTS) 10-12 weeks
Number of subjects: 249
Study: 37150783

Group type: EXPERIMENTAL
Intervention: Repeat revascularization (RR) within 5 years
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Repeat revascularization (RR) within 5 years in the PCI arm
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Repeat revascularization (RR) within 5 years in the CABG arm
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Patients requiring RR who underwent PCI as initial revascularization
Number of subjects: 1800
Study: 34230562

Group type: EXPERIMENTAL
Intervention: ABUS
Number of subjects: 1947

Group type: EXPERIMENTAL
Intervention: HHUS
Number of subjects: 1947
Study: 33137120

Group type: EXPERIMENTAL
Intervention: Single SNP-based alternative method for causal inference
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steiger’s method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bi-directional MR
Number of subjects: 0
Study: 34348576

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) as an adjunct to anti-seizure medications (ASMs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-seizure medications (ASMs) only
Number of subjects: 0
Study: 36454580

Group type: EXPERIMENTAL
Intervention: Tucatinib in combination with trastuzumab and capecitabine
Number of subjects: 612

Group type: COMPARATOR
Intervention: Placebo in combination with trastuzumab and capecitabine
Number of subjects: 612
Study: 33373672

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care with polyethylene bags
Number of subjects: 423

Group type: COMPARATOR
Intervention: Skin-to-skin care alone
Number of subjects: 423
Study: 32381013

Group type: EXPERIMENTAL
Intervention: Toolkit + implementation facilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Toolkit + implementation as usual
Number of subjects: 0
Study: 34779542

Group type: EXPERIMENTAL
Intervention: Omega-3 LCPUFA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sunflower oils (placebo)
Number of subjects: 12
Study: 33829720

Group type: EXPERIMENTAL
Intervention: 40% miswak mouthwash
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 60
Study: 34515160

Group type: EXPERIMENTAL
Intervention: RPM-APD
Number of subjects: 57

Group type: COMPARATOR
Intervention: T-APD
Number of subjects: 57
Study: 34988963

Group type: EXPERIMENTAL
Intervention: Ilioinguinal/iliohypogastric block (Group I)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sacral epidural block (Group S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group S)
Number of subjects: 60
Study: 36116461

Group type: EXPERIMENTAL
Intervention: V116-1 (2 μg per pneumococcal polysaccharide [PnP] per 0·5 mL)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: V116-2 (4 μg per PnP per 1·0 mL)
Number of subjects: 600

Group type: COMPARATOR
Intervention: PPSV23 (25 μg per PnP per 0·5 mL)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: V116 (4 μg per PnP per 1·0 mL)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: V116-1
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: V116-2
Number of subjects: 600

Group type: COMPARATOR
Intervention: PPSV23
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: V116
Number of subjects: 600
Study: 34283711

Group type: EXPERIMENTAL
Intervention: Sleep Scholar (internet-based insomnia intervention)
Number of subjects: 38
Study: 32046752

Group type: EXPERIMENTAL
Intervention: Clinical indices for diagnosing PCOS (experimental group 1)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Metabolomic indices for diagnosing PCOS (experimental group 2)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Healthy control group (no PCOS)
Number of subjects: 276
Study: 34958620

Group type: EXPERIMENTAL
Intervention: Oxytocin plus misoprostol (400 µg sublingual)
Number of subjects: 1036

Group type: COMPARATOR
Intervention: Oxytocin plus placebo
Number of subjects: 1036
Study: 33350222

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Tongtian Oral Liquid
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Zhengtian Pills
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Toutongning Capsules
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Yangxue Qingnao Granules
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Tianshu Capsules
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Xuefu Zhuyu Capsules
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Danzhen Toutong Capsules
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Chuanxiong Qingnao Granules
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Songling Xuemaikang Capsules
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Yuntongding Capsules
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flunarizine combined with Danqi Soft Capsules
Number of subjects: 52
Study: 34856443

Group type: EXPERIMENTAL
Intervention: Continuum condition
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Categorical condition
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 271
Study: 33314487

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 621

Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 621
Study: 36257512

Group type: EXPERIMENTAL
Intervention: Rounded shoulder above the DE (SA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hollow chamfer above the DE (CA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Butt joint above the DE (BJ)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rounded shoulder below the DE (SB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Chamfer below the DE (CB)
Number of subjects: 50
Study: 33839692

Group type: EXPERIMENTAL
Intervention: Copanlisib plus rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus rituximab
Number of subjects: 0
Study: 32350975

Group type: EXPERIMENTAL
Intervention: Preserved saline (PS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Preservative-free saline (PFS)
Number of subjects: 68
Study: 35491963

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g IV with morphine 0.1 mg/kg
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo IV with morphine 0.1 mg/kg
Number of subjects: 220
Study: 33838141

Group type: EXPERIMENTAL
Intervention: Psychologically informed video (n=34)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control video (n=32)
Number of subjects: 66
Study: 35589575

Group type: COMPARATOR
Intervention: 20 µg hepatitis B vaccine at 0-1-6 month
Number of subjects: 290

Group type: COMPARATOR
Intervention: 20 µg hepatitis B vaccine at 0-1-2-6 month
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: 60 µg hepatitis B vaccine at 0-1-2-6 month
Number of subjects: 290
Study: 35026342

Group type: EXPERIMENTAL
Intervention: Vunakizumab 40 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Vunakizumab 80 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Vunakizumab 160 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Vunakizumab 240 mg
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 34216635

Group type: EXPERIMENTAL
Intervention: Non-pharmaceutical interventions (NPIs) implemented during the Covid-19 pandemic
Number of subjects: 0
Study: 33316457

Group type: EXPERIMENTAL
Intervention: PGx test results provided at the beginning of an episode of care
Number of subjects: 2000

Group type: COMPARATOR
Intervention: PGx test results provided 6 months later
Number of subjects: 2000
Study: 33067301

Group type: EXPERIMENTAL
Intervention: 12 weeks of wheelchair user-modified upper-body rowing exercise, 30 min three times per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal lifestyle (control group)
Number of subjects: 0
Study: 34202167

Group type: EXPERIMENTAL
Intervention: 0.4% KGM
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 0.8% KGM
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0% KGM (Control)
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.4% KGM (Control)
Number of subjects: 13
Study: 32465366

Group type: EXPERIMENTAL
Intervention: Point of Care (POC) management of coagulopathy using ROTEM, PFA 200, Multiplate, and 5% albumin solution
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-POC management based on anesthesiologist's experience
Number of subjects: 46
Study: 33527352

Group type: EXPERIMENTAL
Intervention: Lateral-curvature group (n=51)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Medial-curvature group (n=39)
Number of subjects: 90
Study: 35435961

Group type: EXPERIMENTAL
Intervention: DEC-C (35 mg decitabine and 100 mg cedazuridine)
Number of subjects: 133

Group type: COMPARATOR
Intervention: IV decitabine (20 mg/m2 once daily for the first 5 days of each 28-day cycle)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: DEC-C
Number of subjects: 133
Study: 32920476

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioural intervention provided by a mental health nurse practitioner (MHNP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 33818221

Group type: EXPERIMENTAL
Intervention: Horticultural therapy (HT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 32741499

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT) protocol
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control Episodic Recent Thinking (ERT) protocol
Number of subjects: 28
Study: 35228493

Group type: EXPERIMENTAL
Intervention: Textured Soybean Protein (40 g in 2 dishes for 4 weeks)
Number of subjects: 47
Study: 32241819

Group type: EXPERIMENTAL
Intervention: Knee arthroscopy
Number of subjects: 634925

Group type: EXPERIMENTAL
Intervention: Shoulder arthroscopy
Number of subjects: 634925

Group type: EXPERIMENTAL
Intervention: Wrist arthroscopy
Number of subjects: 634925

Group type: EXPERIMENTAL
Intervention: Elbow arthroscopy
Number of subjects: 634925

Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Number of subjects: 634925

Group type: EXPERIMENTAL
Intervention: Ankle arthroscopy
Number of subjects: 634925
Study: 32811427

Group type: EXPERIMENTAL
Intervention: High-dose rabeprazole (20 mg twice daily)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard-dose rabeprazole (20 mg once daily)
Number of subjects: 73
Study: 34890455

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (75 IU)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Local anesthetic (control group)
Number of subjects: 48
Study: 34760994

Group type: EXPERIMENTAL
Intervention: oscillating positive airway pressure (oPEP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: autogenic drainage (AD)
Number of subjects: 51
Study: 34258833

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) intervention
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Barriers to SDM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Facilitators of SDM
Number of subjects: 40
Study: 34915654

Group type: EXPERIMENTAL
Intervention: Prefabricated caps for occlusal recording
Number of subjects: 12

Group type: COMPARATOR
Intervention: Polyvinyl siloxane occlusal record
Number of subjects: 12
Study: 34487151

Group type: EXPERIMENTAL
Intervention: Pradefovir 30 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Pradefovir 45 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Pradefovir 60 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Pradefovir 75 mg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 240
Study: 34016045

Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (Group R) - induction dose of 0.2 mg/kg and maintenance dosage of 1.0 mg/kg/h
Number of subjects: 82

Group type: COMPARATOR
Intervention: Propofol (Group P) - induction dose of 1.5–2.0 mg/kg and maintenance dosage of 3.0–6.0 mg/kg/h
Number of subjects: 82

Group type: COMPARATOR
Intervention: Propofol (Group P)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Remimazolam besylate (Group R)
Number of subjects: 82
Study: 32386275

Group type: EXPERIMENTAL
Intervention: Low dose of tomato juice
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High dose of tomato juice
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tomato juice intake
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low and high amounts of tomato juice
Number of subjects: 14
Study: 36167377

Group type: EXPERIMENTAL
Intervention: Geriatric assessment summary and management recommendations with communication support
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 210
Study: 34490696

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (FS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate (FF)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ferrous ascorbate (FA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Carbonyl iron (CI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: All iron salts (FS, FF, FA, CI)
Number of subjects: 120
Study: 32056945

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (BCBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Minimally-directive supportive psychotherapy (control)
Number of subjects: 24
Study: 35351366

Group type: EXPERIMENTAL
Intervention: Combined model based on radiomic features, imaging characteristics, and serum tumor biomarkers.
Number of subjects: 156
Study: 33945343

Group type: EXPERIMENTAL
Intervention: Minilaparoscopy (Group M)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard laparoscopy (Group S)
Number of subjects: 46
Study: 35437951

Group type: EXPERIMENTAL
Intervention: Almonertinib (110 mg) under fasting conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Almonertinib (110 mg) under fed conditions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adverse reactions in fasting group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Adverse reactions in fed group
Number of subjects: 20
Study: 34574456

Group type: EXPERIMENTAL
Intervention: HearWell Design Team
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HearWell
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 33571954

Group type: EXPERIMENTAL
Intervention: Men with metastatic UTUC
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Women with metastatic UTUC
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Increasing age in men
Number of subjects: 1340

Group type: EXPERIMENTAL
Intervention: Increasing age in women
Number of subjects: 1340
Study: 34843964

Group type: EXPERIMENTAL
Intervention: Improved CRT response (CCS)
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Improved CRT response (LVESVi)
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Stabilized CRT response (CCS)
Number of subjects: 1603

Group type: EXPERIMENTAL
Intervention: Stabilized CRT response (LVESVi)
Number of subjects: 1603

Group type: COMPARATOR
Intervention: Worsened CRT response
Number of subjects: 1603
Study: 33012643

Group type: EXPERIMENTAL
Intervention: Generic drug approval process video
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bioequivalence video
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 103
Study: 32532581

Group type: EXPERIMENTAL
Intervention: Endotracheal tube introducer with Macintosh laryngoscope
Number of subjects: 52

Group type: COMPARATOR
Intervention: Macintosh laryngoscope alone
Number of subjects: 52
Study: 34344706

Group type: EXPERIMENTAL
Intervention: OKZ 64 mg every 2 weeks
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: OKZ 64 mg every 4 weeks
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 428
Study: 34605045

Group type: EXPERIMENTAL
Intervention: BMS-986263 (90 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: BMS-986263 (45 mg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 33243605

Group type: EXPERIMENTAL
Intervention: 4-gene prognostic signature constructed using LASSO Cox analysis and multivariate Cox analysis in the training set.
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: High-risk group identified by the prognostic signature.
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating risk score and clinical factors.
Number of subjects: 539
Study: 35065784

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (2000 mg peanut protein per day for 134 weeks)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy
Number of subjects: 146
Study: 32295776

Group type: EXPERIMENTAL
Intervention: Mobile Technology Plus (MT+) intervention consisting of a smartphone self-monitoring application (Lose-It premium), discussion group, SMS text-based support, and Wi-Fi scale.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Basic Mobile Technology (MT) intervention consisting of a self-monitoring application (Lose-It basic).
Number of subjects: 80
Study: 616034075

Group type: EXPERIMENTAL
Intervention: CTA-based strategy for ruling-out acute coronary syndrome (ACS)
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Clinical risk factors (age, sex, tobacco use, diabetes, race)
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Random forest model based on clinical risk factors
Number of subjects: 1735

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score
Number of subjects: 1735
Study: 34635391

Group type: EXPERIMENTAL
Intervention: CYD‐TDV vaccine
Number of subjects: 335

Group type: COMPARATOR
Intervention: No vaccination (control)
Number of subjects: 335
Study: 33253816

Group type: EXPERIMENTAL
Intervention: Low-MI (<0.2) imaging with intermittent high-MI impulses (five frames, 1.8 MHz, MI = 1.0–1.2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-MI (<0.2) imaging alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intermittent high-MI impulses
Number of subjects: 50
Study: 32641012

Group type: EXPERIMENTAL
Intervention: Daily AIH (15, 90s episodes at 10.0% O2 with 60s intervals at 20.9% O2)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Daily SHAM (15, 90s episodes at 20.9% O2 with 60s intervals at 20.9% O2)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Daily AIH + WALK (60-min walking practice)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Daily SHAM + WALK (60-min walking practice)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Daily AIH and SHAM interventions
Number of subjects: 85
Study: 34543890

Group type: EXPERIMENTAL
Intervention: Prenatal DHA (400 mg/day)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1094
Study: 32214294

Group type: EXPERIMENTAL
Intervention: SHP + PRF (SHP-N combined with pulsed radiofrequency of the sacral roots S2-4)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: SHP + PRF
Number of subjects: 58

Group type: COMPARATOR
Intervention: SHP
Number of subjects: 58